Prevalence of Polyendocrine Metabolic Ovarian Syndrome in Patients Diagnosed With Acne Vulgaris in Sohag University Hospital
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age15-49
SponsorSohag University
About this trial
The aim of this study is to determine the prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among female patients diagnosed with acne vulgaris in Sohag university hospital
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Female patients at childbearing age ( 15 - 49 years) (World Health, 2024).
Patients clinically diagnosed with acne vulgaris.
Patients diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) according to the 2023 International Evidence-based Guideline for PCOS diagnosis.
Diagnostic criteria for PMOS diagnosis in adults : (Forslund et al., 2024).
Disqualifiers
Pregnant women.
Lactating mothers
Women diagnosed with other acneiform lesions
Women on certain drug treatments like oral contraceptive pills, ovarian stimulating drugs and oral hypoglycemic agents like metformin.
Trial population
Female patients diagnosed with acne vulgaris
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
90 Participants
are grouped into 1 trial groupGroup A: Patients diagnosed with acne vulgaris
Trial outcomes
Primary outcomes
1
Prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among patients diagnosed with acne vulgaris in Sohag university hospital
Time frame
Over 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov